Compare CDNA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | COLL |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2007 | 2015 |
| Metric | CDNA | COLL |
|---|---|---|
| Price | $21.86 | $32.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $27.60 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 672.4K | 454.6K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | $48,324,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $16.01 | $8.01 |
| Revenue Next Year | $11.31 | N/A |
| P/E Ratio | ★ N/A | $19.13 |
| Revenue Growth | 18.93 | ★ 23.62 |
| 52 Week Low | $10.96 | $26.35 |
| 52 Week High | $23.24 | $50.79 |
| Indicator | CDNA | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 64.28 | 42.03 |
| Support Level | $16.63 | $31.18 |
| Resistance Level | $23.24 | $36.22 |
| Average True Range (ATR) | 1.39 | 1.36 |
| MACD | 0.36 | 0.09 |
| Stochastic Oscillator | 81.12 | 27.82 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.